On Friday, Merck & Co., Inc. (NYSE:MRK)’s shares declined -3.49% to $52.08.
MSD, known as Merck (MRK) in the United States and Canada, recently declared that omarigliptin, MSD’s investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to MSD’s once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients’ HbA1c* levels from baseline, with similar HbA1c reductions achieved in both groups. The head-to-head study was designed to evaluate once-weekly treatment with omarigliptin 25 mg contrast to 100 mg of JANUVIA once daily, a widely prescribed DPP-4 inhibitor worldwide. Results were presented during an oral session at the 51st European Association for the Study of Diabetes (EASD) Annual Meeting.
MSD presented a new drug application to the Japanese Pharmaceuticals and Medical Devices Agency in November 2014 and plans to submit for regulatory approval of omarigliptin in the United States by the end of 2015. The clinical development program for omarigliptin, O-QWEST (Omarigliptin Q Weekly Efficacy and Safety in Type 2 Diabetes), comprises 10 Phase 3 clinical trials involving about 8,000 patients with type 2 diabetes.
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases.
Northstar Realty Finance Corp (NYSE:NRF)’s shares dropped -0.28% to $14.46.
NorthStar Asset Management Group Inc. (NSAM) and NorthStar Realty Finance Corp. (NRF) declared that they are planned to present at the JMP Financial Services & Real Estate Conference on Monday, September 21, 2015 at the St. Regis Hotel in New York, NY.
Separate company presentations are planned for the following times on Monday, September 21, 2015:
NorthStar Asset Management Group Inc.’s presentation, led by Al Tylis, NSAM’s Chief Executive Officer, is planned for 2:30 p.m. ET. A live audio webcast of the presentation will be accessible on NSAM’s website at www.nsamgroup.com and an audio replay of the presentation will be archived on the website for 60 days.
At the end of Friday’s trade, NVIDIA Corporation (NASDAQ:NVDA)‘s shares dipped -0.09% to $23.29.
Japan’s largest IT society, the Information Processing Society of Japan (IPSJ), honored NVIDIA ( NVDA) Chief Scientist and Senior Vice President of Research Bill Dally with the Funai Achievement Award for his extraordinary achievements in the field of computer science and education.
Dally is the first non-Japanese scientist to receive the award since the first two awards were given out in 2002 to Alan Kay (a pioneer in personal computing) and in 2003 to Marvin Minsky (a pioneer in artificial intelligence).
The Funai Achievement Award recognizes Dally’s accomplishments in computer architecture, particularly in the areas of parallel computing and Very Large Scale Integration processing. The IPSJ noted that Dally has made major contributions in education at the Massachusetts Institute of Technology, Stanford University, and in industry as NVIDIA’s chief scientist.
NVIDIA Corporation operates as a visual computing company in the United States, Taiwan, China, the rest of Asia Pacific, Europe, and other Americas. The company operates through two segments, GPU and Tegra Processors. The GPU segment offers processors, which comprise GeForce for PC gaming; Quadro for design professionals working in computer-aided design, video editing, special effects, and other creative applications; Tesla GPU accelerators for researchers, deep learning, and big-data analysts; and GRID for cloud-based streaming on gaming devices.
3M Co (NYSE:MMM), ended its Friday’s trading session with -2.33% loss, and closed at $139.62.
3M Safety and Graphics Business Group declares a minority equity investment in StrongArm Technologies Inc., a New York-based startup that is focused on creating innovative safety products for the industrial workforce.
StrongArm designs and manufactures patent protected products aimed to enhance the safety and productivity of workers engaged in manual lifting and materials handling. The company has launched ErgoSkeleton™ personal performance equipment, ergonomically influenced exoskeleton products for industrial workers identified as V22 and FLx. The V22 is a passive ErgoSkeleton™ that assists workers lift heavy boxes by redistributing the load on the body, allowing the user to lift safer and for longer distances. The FLx is a streamlined ErgoSkeleton™ that supports proper posture and reduces fatigue.
3M Company operates as a diversified technology company worldwide. Its Industrial segment offers tapes; coated, non-woven, and bonded abrasives; adhesives; ceramics; sealants; specialty materials; filtration products; closure systems for personal hygiene products; acoustic systems products; automotive components; abrasion-resistant films; structural adhesives; and paint finishing and detailing products.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
